Premium
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin ( FLAI ) provides the most useful prognostic information
Author(s) -
Minetto Paola,
Guolo Fabio,
Clavio Marino,
Kunkl Annalisa,
Colombo Nicoletta,
Carminati Enrico,
Fugazza Giuseppina,
Matarese Simona,
Guardo Daniela,
Ballerini Filippo,
Di Grazia Carmen,
Raiola Anna M.,
Cagnetta Antonia,
Cea Michele,
Miglino Maurizio,
Lemoli Roberto M.,
Gobbi Marco
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15106
Subject(s) - idarubicin , cytarabine , fludarabine , medicine , minimal residual disease , regimen , oncology , surgery , gastroenterology , leukemia , chemotherapy , cyclophosphamide